Bhanji Muna Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
11
Insider Sells Sum
$574,807.00

Insider Activity of Bhanji Muna

According to the SEC Form 4 filings, Bhanji Muna, being in a position of

  1. director at Veracyte, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 3728 shares for $161,553,
    over all time since 2023-05-30, has bought 0 shares, and sold 21158 shares for $590,533.

Biography of Bhanji Muna

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$161,5532100

Comparison of Insiders on Amount of Buys and Sells

2026-10-19SaleVeracyte, Inc.
VCYT
director
1,864
0.0023%
$43.70$81,457+11.87%
2026-09-01SaleVeracyte, Inc.
VCYT
director
1,864
0.0023%
$42.97$80,096+2.51%
2025-06-13SaleVeracyte, Inc.
VCYT
director
4,589
0.0059%
$26.67$122,367+32.39%
2025-05-15SaleCytokinetics, Incorporated
CYTK
director
1,454
0.0012%
$29.73$43,227+103.65%
2025-04-29SaleIntellia Therapeutics, Inc.
NTLA
director
265
0.0003%
$8.50$2,253+44.27%
2025-01-29SaleIntellia Therapeutics, Inc.
NTLA
director
265
0.0003%
$9.97$2,642-3.75%
2024-06-10SaleCytokinetics, Incorporated
CYTK
director
2,000
0.0017%
$52.07$104,140-6.93%
2024-06-10SaleVeracyte, Inc.
VCYT
director
3,870
0.0049%
$20.32$78,634+54.69%
2024-05-28SaleVeracyte, Inc.
VCYT
director
1,539
0.002%
$21.00$32,319+50.58%
2023-10-31SaleIntellia Therapeutics, Inc.
NTLA
director
265
0.0003%
$23.90$6,334-0.06%
2023-07-31SaleIntellia Therapeutics, Inc.
NTLA
director
265
0.0003%
$42.33$11,217-35.54%
2023-07-07SaleCytokinetics, Incorporated
CYTK
director
2,000
0.0021%
$34.12$68,235+41.31%
2023-07-06SaleIntellia Therapeutics, Inc.
NTLA
director
1,867
0.0021%
$39.30$73,373-28.04%
2023-06-16SaleVeracyte, Inc.
VCYT
director
5,893
0.0083%
$26.44$155,786-6.59%
2023-05-30SaleVeracyte, Inc.
VCYT
director
1,539
0.0022%
$25.91$39,875-2.8%
Total: 15
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.